Dehydroemetine precautions: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Dehydroemetine}} {{CMG}} <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: P...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Precautions== | |||
Dehydroemetine should only be considered as a last resort in patients with preexisting cardiac, renal or neuromuscular disease. | |||
It should always be administered in a hospital setting. | |||
<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Amoebiasis and giardiasis: Dehydroemetine | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.1.3.html#Jh2922e.2.1.3 | publisher = | date = | accessdate = }}</ref> | Heart rate and blood pressure should be carefully monitored and treatment should be stopped immediately if tachycardia, severe hypotension or electrocardiographic changes develop. | ||
Weakness and muscular pain frequently precede more serious toxic effects and serve as a warning to reduce dosage.<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Amoebiasis and giardiasis: Dehydroemetine | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.1.3.html#Jh2922e.2.1.3 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 00:37, 31 December 2013
| Dehydroemetine |
|---|
| MEBADIN® Prescribing Information |
| General Information |
| Clinical Information |
| Dosage and Administration |
| Precautions |
| Use in Pregnancy |
| Adverse Effects |
| Drug Interactions |
| Storage |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Precautions
Dehydroemetine should only be considered as a last resort in patients with preexisting cardiac, renal or neuromuscular disease.
It should always be administered in a hospital setting.
Heart rate and blood pressure should be carefully monitored and treatment should be stopped immediately if tachycardia, severe hypotension or electrocardiographic changes develop.
Weakness and muscular pain frequently precede more serious toxic effects and serve as a warning to reduce dosage.[1]